In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2011

A look at financing, M&A, and alliance activity October–December 2011

Executive Summary

Biopharmaceutical company financings more than doubled to $2.7 billion from Q3. There were 23 acquisitions bringing in a total of $17.7 billion. And in alliances there was a focus on biosimilars, oncology and neurology deals, and unique partnerships with clear paths to exits.


Related Content

Ariad: Worth Watching As Its Pipeline Matures
Biopharma In 2011: A Year Of Transition
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
Dendreon Rebounds In Q4 2011, But Can It Keep It Up In 2012?
Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017
Valeant’s Latest M&A Gambit Hits Snag With Ista’s Rejection Of $314 Million Buyout Offer
Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
Roche Agrees To Acquire HCV Biotech Anadys For $230 Million
Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts